New product intros [avapritinib, benzhydrocodone hydrochloride/acetaminophen (new combination), crizanlizumab-tmca (first-in-class), enfortumab vedotin-ejfv (first-in-class), givosiran (first-in-class), lasmiditan succinate (first-in-class), semaglutide (new indication), ubrogepant]

{"title":"New product intros [avapritinib, benzhydrocodone hydrochloride/acetaminophen (new combination), crizanlizumab-tmca (first-in-class), enfortumab vedotin-ejfv (first-in-class), givosiran (first-in-class), lasmiditan succinate (first-in-class), semaglutide (new indication), ubrogepant]","authors":"","doi":"10.1358/dot.2020.56.2.3138014","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":85144,"journal":{"name":"Medicamentos de actualidad. Drugs of today","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicamentos de actualidad. Drugs of today","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1358/dot.2020.56.2.3138014","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
新产品介绍[阿伐替尼、盐酸苯氢可酮/对乙酰氨基酚(新组合)、克里赞利单抗-tmca(同类首创)、安替妥单抗-ejfv(同类首创)、吉伏昔兰(同类首创)、琥珀酸拉斯米坦(同类首创)、西马鲁肽(新适应症)、增稠剂]
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信